3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Plasma cell
2
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
162
Fulvestrant
157
Trastuzumab
156
pembrolizumab
146
Letrozole
137
Carboplatin
118
pertuzumab
104
Capecitabine
104
Specimen Handling
102
Cyclophosphamide
102
Anastrozole
90
palbociclib
86
abemaciclib
82
Magnetic Resonance Spectroscopy
81
exemestane
76
Docetaxel
76
Tamoxifen
75
ribociclib
74
trastuzumab deruxtecan
68
Radiotherapy
62
Biopsy
59
Surveys and Questionnaires
55
Gemcitabine
53
130-nm albumin-bound paclitaxel
53
olaparib
52
sacituzumab govitecan
51
Blood Specimen Collection
51
Standard of Care
49
Taxes
48
eribulin
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Breast
×
1 year
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled